Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: A population-based study

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Putila, Joseph ^a   Remick, Scot C ^a,b   Guo, Nancy Lan ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGED; ARTICLE; BOOTSTRAPPING; BRIER SCORE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; FEASIBILITY STUDY; FEMALE; HARRELL C SCORE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; NAGELKERKE R SCORE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROBABILITY; PROGNOSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; CANCER REGISTRY; COHORT ANALYSIS; DECISION SUPPORT SYSTEM; DEMOGRAPHY; FACTUAL DATABASE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; POPULATION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; VALIDATION STUDY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; DEMOGRAPHY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POPULATION; PROGNOSIS; RISK FACTORS; SEER PROGRAM; VALIDATION STUDIES AS TOPIC;

EID: 79952153997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017493     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Hoffman PC, Mauer AM, Vokes EE, (2000) Lung cancer. Lancet 355: 479-485.
3. Naruke T, Goya T, Tsuchiya R, Suemasu K, (1988) Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96: 440-447.
4. Dehing-Oberije C, Aerts H, Yu S, De RD, Menheere P, et al. (2010) Development and Validation of a Prognostic Model Using Blood Biomarker Information for Prediction of Survival of Non-Small-Cell Lung Cancer Patients Treated With Combined Chemotherapy and Radiation or Radiotherapy Alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys.
5. Dehing-Oberije C, Yu S, De RD, Meersschout S, Van BK, et al. (2009) Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 74: 355-362.
6. Dehing-Oberije C, De RD, van der WH, Hochstenbag M, Bootsma G, et al. (2008) Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 70: 1039-1044.
7. Werner-Wasik M, Swann RS, Bradley J, Graham M, Emami B, et al. (2008) Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70: 385-390.
8. Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, et al. (2006) Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 64: 449-454.
9. Solan MJ, Werner-Wasik M, (2003) Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 21: 64-73.
10. Ball D, Smith J, Wirth A, Mac MM, (2002) Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 54: 1007-1013.
11. Brundage MD, Davies D, Mackillop WJ, (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057.
12. Bradley JD, Ieumwananonthachai N, Purdy JA, Wasserman TH, Lockett MA, et al. (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52: 49-57.
13. Brown JS, Eraut D, Trask C, Davison AG, (1996) Age and the treatment of lung cancer. Thorax 51: 564-568.
14. O'Rourke MA, Feussner JR, Feigl P, Laszlo J, (1987) Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly. JAMA 258: 921-926.
15. Visbal AL, Williams BA, Nichols FC III, Marks RS, Jett JR, et al. (2004) Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 78: 209-215.
16. Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537.
17. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK, (2002) Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 162: 1985-1993.
18. Dalton WS, Friend SH, (2006) Cancer biomarkers-an invitation to the table. Science 312: 1165-1168.
19. American Joint Committee on Cancer (2010) AJCC Cancer Staging Manual. New York Springer-Verlag.
20. SEER, (2010) Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER 9 Regs Research Data, Nov 2009 Sub (1973-2007) <Katrina/Rita Population Adjustment>- Linked To County Attributes- Total U.S., 1969-2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission.
21. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
22. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, et al. (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54: 774-781.
23. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, et al. (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54: 774-781.
24. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van ZN, et al. (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-935.
25. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565.
26. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, et al. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1-4.
27. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824.
28. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98: 13790-13795.
29. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
30. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA, (2005) Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 172: 729-737.
31. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, et al. (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356: 11-20.
32. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, et al. (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355: 570-580.
33. Raponi M, Zhang Y, Yu J, Chen G, Lee G, et al. (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66: 7466-7472.
34. Guo L, Ma Y, Ward R, Castranova V, Shi X, et al. (2006) Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 12: 3344-3354.
35. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, et al. (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14: 8213-8220.
36. Ludwig JA, Weinstein JN, (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856.
37. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, et al. (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23: 2716-2725.
38. Birim O, Kappetein AP, Waleboer M, Puvimanasinghe JP, Eijkemans MJ, et al. (2006) Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg 132: 491-498.
39. Firat S, Byhardt RW, Gore E, (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54: 357-364.